Association for Accessible Medicines filed 5 comments on this docket between Mar 31, 2021 and Oct 25, 2021. 1 other organizations filed here. The comment window closed 994d ago.
Comments from the Association for Accessible Medicines (AAM) regarding Docket No: FDA-2020-D-1136: Development of Abbreviated New Drug Applications During the COVID-19 Pandemic – Questions and Answers
Comments from The Association for Accessible Medicines (AAM) on behalf of our member companies, regarding docket No: FDA-2020-D-1136: Development of Abbreviated New Drug Applications During the COVID-19 Pandemic – Questions and Answers.
Comments from The Association for Accessible Medicines (AAM) on behalf of our member companies, regarding docket No: FDA-2020-D-1136-0057: Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency; Guidance for Industry.
Comments from The Association for Accessible Medicines (AAM) on behalf of our member companies, regarding docket No. FDA-2020-D-1136: COVID-19 Container Closure System and Component Changes: Glass Vials and Stoppers.
Comments from The Association for Accessible Medicines (AAM) on behalf of our member companies, regarding docket No. FDA-2020-D-1136-0035, Manufacturing, Supply Chain, and Drug and Biological Product Inspections During COVID-19 Public Health Emergency Questions and Answers Guidance for Industry.
No abstract recorded.
View on regulations.gov →